Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
25.26
-0.56 (-2.17%)
Mar 5, 2026, 4:00 PM EST - Market closed
Zenas BioPharma Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Zenas BioPharma stock have an average target of 41.14, with a low estimate of 19 and a high estimate of 55. The average target predicts an increase of 62.87% from the current stock price of 25.26.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Zenas BioPharma stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 3 | 5 | 5 | 4 | 3 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 6 | 8 | 8 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $44 | Strong Buy | Reiterates | $44 | +74.19% | Feb 10, 2026 |
| Morgan Stanley | Morgan Stanley | Buy → Hold Downgrades $37 → $19 | Buy → Hold | Downgrades | $37 → $19 | -24.78% | Jan 6, 2026 |
| Wedbush | Wedbush | Buy Reiterates $45 | Buy | Reiterates | $45 | +78.15% | Dec 22, 2025 |
| Evercore ISI Group | Evercore ISI Group | Buy Initiates $55 | Buy | Initiates | $55 | +117.74% | Nov 26, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $34 → $37 | Buy | Maintains | $34 → $37 | +46.48% | Nov 13, 2025 |
Financial Forecast
Revenue This Year
29.75M
from 5.00M
Increased by 495.00%
Revenue Next Year
n/a
from 29.75M
EPS This Year
-4.15
from -11.89
EPS Next Year
-4.65
from -4.15
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 89.3M | n/a | ||||
| Avg | 29.8M | n/a | ||||
| Low | 9.8M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 1,685.0% | - | ||||
| Avg | 495.0% | - | ||||
| Low | 96.0% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.73 | -3.64 | ||||
| Avg | -4.15 | -4.65 | ||||
| Low | -5.23 | -5.47 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.